OICR (Cellax)

oicr.on.ca
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Cellax is a self-assembling nanoparticle drug-polymer conjugate that selectively targets tumour cells for enhanced cancer treatment with fewer side effects.

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.